NCT01039805View on ClinicalTrials.gov

Evaluation of Single Doses of GSK962040 in Critically Ill Patients With Enteral Feed Intolerance

PHASE2CompletedINTERVENTIONAL

Enrollment

34

Participants

Timeline

Start Date

December 31, 2009

Primary Completion Date

July 31, 2011

Study Completion Date

July 31, 2011

Conditions

Gastroparesis

Interventions

DRUG

GSK962040 (50 mg)

Cohort 1 = 50 mg

DRUG

Placebo

matching placebo

DRUG

GSK962040 (75 mg)

Cohort 2 = 75 mg

Trial Locations (1)

5000

GSK Investigational Site, Adelaide

Sponsors

Lead Sponsor

GlaxoSmithKline

All Listed Sponsors

lead

GlaxoSmithKline

INDUSTRY

NCT01039805 - Evaluation of Single Doses of GSK962040 in Critically Ill Patients With Enteral Feed Intolerance | Biotech Hunter | Biotech Hunter